Zelda Collaborates with Emerald Clinics to Access Real-world Data for Medicinal Cannabis Patients

- Zelda enters strategic collaboration with Australia-based Emerald Clinics to access clinical data from patients treated with medicinal cannabis for pain and insomnia

- Zelda will gain strategic access to:
  - Real-world patient data linked to medicinal cannabis prescriptions
  - Real-time data from patients treated with Zelda’s clinically validated formulations, which the company is aiming to commercially launch in 2020
  - Expanded access to new clinical trial sites to accelerate patient recruitment and reduce costs

- Emerald collaboration reinforces Zelda’s competitive advantage in clinical validation of medicinal cannabis and downstream value-adding

- Supports Zelda’s path to rapid commercialisation in global markets

Zelda Therapeutics Limited (ASX: ZLD, OTCQB: ZLDAF) is pleased to announce it has entered into a strategic collaboration with Australia-based healthcare technology and services company Emerald Clinics (Emerald), which owns and operates an Australian network of dedicated medicinal cannabis clinics.

Under the terms of the agreement Emerald will provide access to de-identified real-world longitudinal data collected from patients prescribed cannabis medicines for treatment of pain and/or insomnia. Data will include details regarding cannabis dosages prescribed to patients, their responses to treatment and the impact on usage of non-cannabis medicines such as opioids.

This information will inform Zelda’s ongoing clinical trial strategy, which is focused on developing new cannabis-based treatments to reduce opioid usage in patients with chronic pain as well as patients with insomnia and autism.

The agreement also includes an option for Zelda to access real-world data collected from patients prescribed Zelda-branded cannabis products, which the company is aiming to bring...
to market in 2020. A further option is for Zelda to engage Emerald to assist with the design and patient recruitment for future clinical trials.

Zelda will pay Emerald an initial fee of $40,000 to access existing de-identified data for patients prescribed medicinal cannabis for treatment of pain and/or insomnia, while subscription fees for the additional data-modules will be negotiated at a later date.

The strategic collaboration with Emerald further establishes Zelda at the forefront of efforts globally to develop clinically validated cannabis medicines.

Zelda Therapeutics Managing Director, Dr Richard Hopkins, commented: “Australia’s commitment to developing a highly regulated market for prescription cannabis medicines means this country is now a global leader in collection of high-quality longitudinal clinical data relating to patients treated with medicinal cannabis.

We believe Emerald’s approach to collection and curation of patient data makes this information a very valuable commodity world-wide.

Being able to access real-world data, in real-time, from patients treated with regulated cannabis medicines – including, in the near future, our own clinically validated products – will provide Zelda with a significant competitive advantage. This information will inform the design of future clinical trials, reduce the risks and costs of development and accelerate the path to market.

These key value-adding features will further differentiate Zelda from its global peers and enhance the commercialisation opportunities for the company.”

Emerald’s Chief Executive Officer, Dr Michael Winlo, said: “We’re delighted to be working with clinically-focussed companies such as Zelda Therapeutics. This collaboration validates Emerald’s unique care model that emphasises the captures of high-quality data to improve the development of cannabis medicines for patients.”

Tim Slate

Company Secretary
About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics Ltd is an Australian-based bio-pharmaceutical company developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company is undertaking:

- **A human clinical trial program** focused on insomnia, autism and opioid reduction with activities in Australia and the USA.
- **A pre-clinical research program** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

The company conducts this work in partnership with world-leading researchers and organisations including Complutense University in Madrid, Spain; Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent’s Hospital in Melbourne, Australia; and the Children’s Hospital of Philadelphia (CHOP) in the United States.

Zelda has also formed a strategic partnership with European medicinal cannabis group HAPA Medical BV, to access HAPA’s EU-GMP grade manufacturing capabilities and accessing its German distribution network providing a credible and rapid path to commercialisation for successful clinically validated formulations.

About Emerald Clinics (www.emeraldclinics.com.au)

Emerald Clinics is a healthcare technology and services company incorporated in March 2018 whose mission is to improve lives, by learning from the experience of every patient that is treated with a cannabinoid medicine. Our team includes specialist physicians, experienced General Practitioners and clinical trials experts to deliver best-practice care for patients who have exhausted conventional therapies in Australia. Emerald Clinics currently has two Australian locations with a third opening in 2019.

**For further information contact:**

**Contacts**
Dr Richard Hopkins  
Managing Director  
+61 405 656 868  
rhopkins@zeldatherapeutics.com

**Monsoon Communications**
Rudi Michelson  
+61 3 9620 3333  
rudim@monsoon.com

**Registered Address**
Level 26, 140 St Georges Terrace,  
Perth Western Australia 6000  
Tel: +61 8 6558 0886  
E: enquiries@zeldatherapeutics.com